🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Mereo BioPharma Group plc (MREO)
NASDAQ: MREO · Real-Time Price · USD
0.2750
-0.0143 (-4.94%)
At close: Nov 19, 2026, 4:00 PM EST
0.2870
+0.0120 (4.36%)
After-hours: Nov 19, 2026, 7:30 PM EST

Mereo BioPharma Group Stock Forecast

MREO's stock price has decreased by -84.89% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

According to 8 analysts polled by S&P Global, Mereo BioPharma Group stock has a consensus rating of "Buy" and an average price target of $1.95. The average 1-year stock price forecast is 607.27% higher than the current stock price, while the lowest is $0.98 (+255.42%) and the highest is $2.93 (+966.55%).

Price Target: $1.95 (+607.27%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$0.98$1.95$1.92$2.93
Change+255.42%+607.27%+599.27%+966.55%

Analyst Ratings

The average analyst rating for Mereo BioPharma Group stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingMay '26Jul '26Aug '26Sep '26Oct '26Nov '26
Strong Buy444444
Buy111111
Hold332222
Sell001111
Strong Sell000000
Total888888

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
BTIG
BTIG
Buy
Maintains
$1
BuyMaintains$1+263.64%Nov 10, 2026
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Maintains
$3
BuyMaintains$3+990.91%Sep 18, 2026
J.P. Morgan
J.P. Morgan
Sell
Reiterates
n/a
SellReiteratesn/an/aSep 15, 2026
LifeSci Capital
LifeSci Capital
Hold
Maintains
n/a
HoldMaintainsn/an/aAug 15, 2026
Needham
Needham
Buy
Maintains
$3
BuyMaintains$3+990.91%Aug 11, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
797.54K
from 500.00K
Increased by 59.51%
Revenue Next Year
19.35M
from 797.54K
Increased by 2,326.81%
EPS This Year
n/a
EPS Next Year
n/a
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
49.37M-10.00M-500.00K797.54K
Revenue Growth
-----59.51%
Operating Income
-28.35M-52.70M-27.14M-45.72M-38.26M-29.75M
Net Income
17.23M-42.22M-29.47M-43.25M-41.88M-27.24M
Free Cash Flow
-----18.71M
No. Analysts
-----4

Revenue Forecast

Revenue202620272028
High805,419.2
Avg797,538.4
Low794,751.4

Revenue Growth

Revenue Growth202620272028
High
61.1%
Avg
59.5%
Low
59.0%

EPS Forecast

EPS202620272028
High-
Avg-
Low-

EPS Growth

EPS Growth20272028
High-
Avg-
Low-